Form 8-K - Current report:
SEC Accession No. 0001837607-24-000092
Filing Date
2024-11-13
Accepted
2024-11-13 16:06:28
Documents
16
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20241113x8k.htm   iXBRL 8-K 41525
2 EX-99 aeon-20241113xex99.htm EX-99 284749
3 GRAPHIC aeon-20241113xex99001.jpg GRAPHIC 3801
  Complete submission text file 0001837607-24-000092.txt   480282

Data Files

Seq Description Document Type Size
4 EX-101.SCH aeon-20241113.xsd EX-101.SCH 4048
5 EX-101.DEF aeon-20241113_def.xml EX-101.DEF 2873
6 EX-101.LAB aeon-20241113_lab.xml EX-101.LAB 17857
7 EX-101.PRE aeon-20241113_pre.xml EX-101.PRE 10679
18 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20241113x8k_htm.xml XML 5103
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 241454116
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)